Document is current
Any future updates will be listed below
-
Authors
Farnung, Jakob https://orcid.org/0000-0002-4619-3421
Slobodyanyuk, Elena https://orcid.org/0000-0003-2077-6917
Wang, Peter Y. https://orcid.org/0000-0002-6129-2815
Blodgett, Lianne W. https://orcid.org/0009-0002-3060-0704
Lin, Daniel H. https://orcid.org/0000-0002-1393-3374
von Gronau, Susanne
Schulman, Brenda A. https://orcid.org/0000-0002-3083-1126
Bartel, David P. https://orcid.org/0000-0002-3872-2856
- License Information
-
More Information
Article History
Received: 21 July 2025
Accepted: 4 February 2026
First Online: 18 March 2026
Competing interests
: D.P.B. has equity in Alnylam Pharmaceuticals, where he is a co-founder and an advisor. B.A.S. is a member of the scientific advisory boards of Proxygen and Lyterian. J.F. provides consultancy to Serac Biosciences. The other authors declare no competing interests.
